A team of scientists, engineers and physicians from Brigham and Women's Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell Medical College have found promising effects of a first-in-class targeted cancer drug called BIND-014 in treating solid tumors.
BIND-014 is the first targeted and programmed nanomedicine to enter human clinical studies. The study was electronically published in Science Translational Medicine on April 4, 2012.
In the study, the researchers demonstrate BIND-014's ability to effectively target a receptor expressed in tumors to achieve high tumor drug concentrations, as well as show remarkable efficacy, safety and pharmacological properties compared to the parent chemotherapeutic drug, docetaxel (Taxotere).
"BIND-014 demonstrates for the first time that it is possible to generate medicines with both targeted and programmable properties that can concentrate the therapeutic effect directly at the site of disease, potentially revolutionizing how complex diseases such as cancer are treated," said Omid Farokhzad, MD, a physician-scientist in the BWH Department of Anesthesiology, associate professor at HMS, and study co- senior author.
"Previous attempts to develop targeted nanoparticles have not successfully translated into human clinical studies because of the inherent difficulty of designing and scaling up a particle capable of targeting, long-circulation via immune-response evasion, and controlled drug release," said Robert Langer, ScD, David H. Koch Institute Professor, MIT and study co-senior author.
According to the researchers, the drug is the first of its kind to reach clinical evaluation and demonstrates a differentially high drug concentration in tumors by targeting drug encapsulated nanoparticles directly to the site of tumors. This leads to substantially better efficacy and safety.
March 21, 2019 - Nanomedicine for cancer immunotherapy: Spherical nucleic acids SciTech EuropaA team has developed a method of optimising spherical nucleic acids, which could revolutionise nanomedicine for cancer immunotherapy.
April 9, 2019 - Clinical Solutions to Provide Clients Products & Services GlobeNewswireAccelerate the Clinical and Commercial Development of Gene and Cell Therapies.